- Home
- MUJ vs TBPH Comparison
MUJ vs TBPH Comparison
Compare MUJ & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUJ
- TBPH
- Stock Information
- Founded
- MUJ 1998
- TBPH 2013
- Country
- MUJ United States
- TBPH United States
- Employees
- MUJ N/A
- TBPH N/A
- Industry
- MUJ Investment Bankers/Brokers/Service
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- MUJ Finance
- TBPH Health Care
- Exchange
- MUJ Nasdaq
- TBPH Nasdaq
- Market Cap
- MUJ 573.3M
- TBPH 464.5M
- IPO Year
- MUJ N/A
- TBPH N/A
- Fundamental
- Price
- MUJ $11.06
- TBPH $11.05
- Analyst Decision
- MUJ
- TBPH Strong Buy
- Analyst Count
- MUJ 0
- TBPH 5
- Target Price
- MUJ N/A
- TBPH $16.60
- AVG Volume (30 Days)
- MUJ 108.0K
- TBPH 251.5K
- Earning Date
- MUJ 01-01-0001
- TBPH 08-04-2025
- Dividend Yield
- MUJ 4.36%
- TBPH N/A
- EPS Growth
- MUJ N/A
- TBPH N/A
- EPS
- MUJ N/A
- TBPH N/A
- Revenue
- MUJ N/A
- TBPH $65,266,000.00
- Revenue This Year
- MUJ N/A
- TBPH $43.18
- Revenue Next Year
- MUJ N/A
- TBPH N/A
- P/E Ratio
- MUJ N/A
- TBPH N/A
- Revenue Growth
- MUJ N/A
- TBPH 6.11
- 52 Week Low
- MUJ $9.74
- TBPH $7.44
- 52 Week High
- MUJ $11.70
- TBPH $11.82
- Technical
- Relative Strength Index (RSI)
- MUJ 63.52
- TBPH 60.81
- Support Level
- MUJ $10.78
- TBPH $10.87
- Resistance Level
- MUJ $10.86
- TBPH $11.44
- Average True Range (ATR)
- MUJ 0.08
- TBPH 0.28
- MACD
- MUJ 0.03
- TBPH -0.01
- Stochastic Oscillator
- MUJ 96.77
- TBPH 62.07
About MUJ Blackrock MuniHoldings New Jersey Quality Fund Inc.
BlackRock MuniHoldings New Jersey Quality Fund Inc is a closed-end management investment company. The investment objective of the company is to provide shareholders with current income exempt from U.S. federal income tax and New Jersey personal income taxes. The fund invests in a portfolio of long-term, investment-grade New Jersey municipal obligations.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).